FOLFOX-based balloon-occluded hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
10.13929/j.issn.1672-8475.2024.09.003
- VernacularTitle:基于FOLFOX方案球囊阻断肝动脉灌注化疗治疗不可切除肝细胞癌
- Author:
Xiangbo AN
1
;
Feng WANG
;
Feng LI
Author Information
1. 大连医科大学附属第一医院介入治疗科,辽宁 大连 116011
- Keywords:
liver neoplasms;
chemotherapy,cancer,regional perfusion;
balloon occlusion
- From:
Chinese Journal of Interventional Imaging and Therapy
2024;21(9):522-526
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of balloon-occluded hepatic artery infusion chemotherapy(b-HAIC)based on FOLFOX regimen for unresectable hepatocellular carcinoma(uHCC).Methods Data of 20 uHCC patients who underwent FOLFOX-based b-HAIC were retrospectively analyzed.According to the dose of fluorouracil in FOLFOX regimen,the patients were divided into low-(600 mg/m2·22 h,n=8),medium-(1200 mg/m2·44 h,n=6)and high-dose group(2400 mg/m2·44 h,n=6).The number of b-HAIC cycles were recorded.Clinical efficacy was evaluated,the objective response rate(ORR)and disease control rate(DCR)were calculated,and changes of alpha-fetoprotein(AFP)after treatment were observed to evaluate the efficacy of b-HAIC.And b-HAIC treatment-related adverse events were recorded.Results One to four cycles of b-HAIC were performed in 20 cases,with the median of 2 cycles.The follow-up times were 7-31 weeks,with the median of 15 weeks.There were 4 cases(4/20,20.00%)of complete response(CR),12(12/20,60.00%)of partial response(PR)and 4(4/20,20.00%)of stable disease(SD),ORR was 80.00%(16/20)and DCR was 100%(20/20).The time for the optimal response ranged from 4 to 16 weeks,with a median of 6 weeks.After treatment,ORR in low-,medium-and high-dose group was 75.00%(6/8),83.33%(5/6)and 83.33%(5/6),respectively,and DCR was 100%in all 3 groups.AFP in 17 cases elevated before b-HAIC reduced at different degrees after treatment.Treatment-related adverse events included upper abdominal pain,nausea and vomiting during perfusion,as well as elevated transaminases and total bilirubin,neutrophil percentage and bone marrow suppression after b-HAIC,all relieved after symptomatic treatment.Conclusion FOLFOX-based b-HAIC had good short-term efficacy and controllable adverse reactions for treating uHCC.
